Nintedanib for the treatment of idiopathic pulmonary fibrosis

Expert Opinion on Pharmacotherapy

Volumn 19, Issue 2, 2018, Pages 167-175

  Varone, Francesco ^a   Sgalla, Giacomo ^a   Iovene, Bruno ^a   Bruni, Teresa ^a   Richeldi, Luca ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Anti fibrotic drugs; idiopathic pulmonary fibrosis; nintedanib; tyrosine kinase inhibition

Indexed keywords

NINTEDANIB; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FIBROSING ALVEOLITIS; HEART INFARCTION; HUMAN; NONHUMAN; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; CELL MOTION; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; METABOLISM;

CELL MOVEMENT; CLINICAL TRIALS AS TOPIC; DIARRHEA; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PROTEIN KINASE INHIBITORS;

EID: 85040964032     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2018.1425681     Document Type: Article

References (59)

1. Meyer KC., Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis. Expert Rev Respir Med. Internet. 2017 [cited 2017 Jun18];11:1–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28345383
2. Raghu G, Chen S-Y, Yeh W-S, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir Med. 2014;2:566–572.
3. Selman M, King TE, Pardo A, et al. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. Internet. 2001 [cited 2017 Jun18];134:136–151. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11177318
4. King TE, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164:1171–1181. Internet. Available from.
5. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810–816.
6. Ley B, Collard HR, King, TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. Internet. 2011 [cited 2017 Oct10];183:431–440. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20935110
7. Richeldi L, Cottin V, Du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med. 2016;113:74–79. Internet. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0954611116300191
8. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. Internet. 2011 [cited 2017 Feb4];183:788–824. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21471066
9. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med [Internet]. 2015;192:e3–e19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26177183
10. Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. Internet. 2017 [cited 2017 Oct10];5:33–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27876247
11. Rogliani P, Calzetta L, Cavalli F, et al. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Pulm Pharmacol Ther. 2016;40:95–103. Internet. Available from: http://linkinghub.elsevier.com/retrieve/pii/S109455391630061X
12. Meyer KC, Decker CA., Role of pirfenidone in the management of pulmonary fibrosis. Ther Clin Risk Manag. Internet. 2017 [cited 2017 Aug24];13:427–437. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28435277
13. Mazzei ME, Richeldi L, Collard HR. Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. Internet. 2015;9:121–129. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25862013
14. King TEJ, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092. Internet. Available from.
15. Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. Internet. 2014;370:2071–2082. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24836310
16. Borie R, Justet A, Beltramo G, et al. Pharmacological management of IPF. Respirology. 2016;21:615–625.
17. Magnini D, Montemurro G, Iovene B, et al. Idiopathic pulmonary fibrosis: molecular endotypes of fibrosis stratifying existing and emerging therapies. Respiration. 2017;93(6):379–395.
18. Varone F, Montemurro G, Macagno F, et al. Investigational drugs for idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. [Internet]. 2017;1–13. Available from: https://www.tandfonline.com/doi/full/10.1080/13543784.2017.1364361
19. Inchingolo R, Condoluci C, Smargiassi A, et al. Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? Expert Opin Pharmacother. [Internet]. 2017;1–12. Available from: https://www.tandfonline.com/doi/full/10.1080/14656566.2017.1383382
20. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med. Internet. 2014;2:933–942. Available from. DOI:10.1016/S2213-2600(14)70232-2
21. Sun L, Tran N, Tang F, et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem. 1998;41:2588–2603.
22. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774–4782.
23. Roth GJ, Heckel A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem. 2009;52:4466–4480.
24. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell [Internet]. 2000;103:211–225. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11057895
25. Grimminger F, Günther A, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J. Internet. 2015;45:1426–1433. Available from http://www.ncbi.nlm.nih.gov/pubmed/25614172%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/17961066%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2737712%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/25745048
26. Tzouvelekis A, Yu G, Lino Cardenas CL, et al. SH2 domain-containing phosphatase-2 is a novel antifibrotic regulator in pulmonary fibrosis. Am J Respir Crit Care Med. 2017;195:500–514.
27. Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov. 2010;9:956–970. Internet. Available from: DOI:10.1038/nrd3297.
28. Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29:976–985.
29. Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. [Internet] 2014;349:209–220.
30. Roth GJ, Binder R, Colbatzky F, et al. Nintedanib: from discovery to the clinic. J Med Chem. 2015;58:1053–1063.
31. Reck M. Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor. Expert Rev Anticancer Ther [Internet]. 2015;15:579–594. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25831142
32. Stopfer P, Rathgen K, Bischoff D, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011;41:297–311.
33. Dallinger C, Trommeshauser D, Marzin K, et al. Pharmacokinetic properties of nintedanib in healthy volunteers and patients with advanced cancer. J Clin Pharmacol. 2016;56:1387–1394.
34. Dhillon S. Nintedanib: a review of its use as second-line treatment in adults with advanced non-small cell lung cancer of adenocarcinoma histology. Target Oncol. 2015;10:303–310.
35. Allen JT, Spiteri MA. Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir Res. Internet. 2002;3:13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11806848
36. Coward WR, Saini G, Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. Internet. 2010;4:367–388. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20952439
37. Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29:976–985. Internet. Available from: internal-pdf://198.204.90.252/Chaudhary-2007-Inhibition of PDGF, VEGF and FG.pdf
38. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434–1445.
39. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079–1087. Internet. DOI:10.1056/NEJMoa1103690
40. Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med. 2016;193:178–185.
41. TM trials. Pneumologie. 2015;69:P254.
42. Raghu G, Wells AU, Nicholson AG, et al. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med. 2017;195:78–85.
43. Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72:340–346. Internet. DOI:10.1136/thoraxjnl-2016-208710
44. Azuma A, Taniguchi H, Inoue Y, et al. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials. Respirology. 2017;22:750–757.
45. Crestani B, Quaresma M, Kaye M, et al. Long-term treatment with nintedanib in patients with IPF: an update from INPULSIS®-ON. Eur Resp J [Internet]. 2016;OA4960: Available from: http://erj.ersjournals.com/lookup/doi/10.1183/13993003.congress-2016.OA4960
46. Wuyts WA, Kolb M, Stowasser S, et al. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of  ≤50 % of predicted value. Lung. 2016;194:739–743.
47. Bonella F, Kreuter M, Hagmeyer L, et al. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiration. 2016;92:98–106.
48. Richeldi L, Kreuter M, Selman M, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax 2017. Internet Available from: http://www.ncbi.nlm.nih.gov/pubmed/28993537.
49. Cottin V. Nintedanib: a new treatment for idiopathic pulmonary fibrosis. Clin Investig (Lond). Internet. 2015;5:621–632. Available from: http://www.future-science.com/doi/10.4155/cli.15.27
50. Corte T, Bonella F, Crestani B, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015;16:116. Internet. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26400368
51. Nathan SD. Evaluating new treatment options. Am J Manag Care. Internet. 2017;23:S183–S190. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18185491
52. Cottin V. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis. Expert Opin Drug Saf. Internet. 2017 [cited 2017 Jun15];16:857–865. Available from: https://www.tandfonline.com/doi/full/10.1080/14740338.2017.1338268
53. Fukihara J, Kondoh Y. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis. Expert Rev Respir Med. Internet. 2016;10:1247–1254. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27744713
54. Milger K, Kneidinger N, Neurohr C, et al. Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. Eur Respir J. 2015;46:1217–1221.
55. Vancheri C, Kreuter M, Richeldi L, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: results of the INJOURNEY trial. Am J Respir Crit Care Med. Internet. 2017;183:1689–1697. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28889759
56. Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. Internet. 2015;45:1382–1392. cited 2017 Jan12. Available from: http://erj.ersjournals.com/content/45/5/1382
57. Flaherty KR, Sussman R, Pesci A, et al. Safety of the combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from an interim analysis after 12 weeks. Am J Respir Crit Care Med. 2017;195:A5398.
58. Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017;4:e000212.
59. Wollin L, Ostermann A, Brauchle V, et al. Nintedanib inhibits pro-fibrotic mediators with relevance in connective tissue disease-associated interstitial lung diseases. Eur Respir J. Sep 2017;50(suppl 61):PA903. doi:10.1183/1393003.congress-2017.PA903.